Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.45 |
| ▸ | VDR | P11473 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | DRD3 | P35462 | 5/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE6D | O43924 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283262 | 0.83 | DRD3 (0.60) | ALOX5NR1H4VDRDRD2DRD3 | |
| SCHEMBL1284122 | 0.70 | DRD3 (0.53) | NR1H4VDRDRD2DRD3 | |
| SCHEMBL1283543 | 0.69 | DRD3 (0.68) | DRD2DRD3ACSS2PDE6D | |
| SCHEMBL10592238 | 0.68 | BCHE (0.61) | — | |
| SCHEMBL1283352 | 0.68 | DRD3 (0.59) | DRD2DRD3ACSS2PDE6D | |
| SCHEMBL20641328 | 0.68 | ACSS2 (0.49) | ALOX5ACSS2ROCK2 | |
| SCHEMBL5794259 | 0.68 | GHSR (0.73) | ABCC1PDE6D | |
| SCHEMBL1283259 | 0.67 | DRD3 (0.61) | DRD2DRD3ACSS2PDE6D | |
| SCHEMBL10592227 | 0.66 | BCHE (0.54) | — | |
| SCHEMBL2357093 | 0.66 | VDR (0.61) | NR1H4VDRACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | ALOX5 1411/4885NR1H4 1565/4885VDR 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.